The lead Ambit Biosciences drug candidate, quizartinib, is currently in phase 3 clinical trials among patients with acute myeloid leukemia (AML). San Diego’s Ambit Biosciences will be bought for a total of 315 mill USD.
Ambit Biosciences press release, Sept. 29, 2014
Daiichi Sankyo purchases US Ambit Biosciences, strengthens oncology pipeline